Interferons (A61K38/21)

ethod for treatment of inoperable asctic forms of ovarian cancer // 2624509
FIELD: medicine.SUBSTANCE: for treatment of inoperable ascitic forms of ovarian cancer, the patients with inoperable stage III-IV of ovarian cancer, receive an abdominal cavity drainage after ascitic fluid removal, then recombinant interferon gamma is injected intraperitoneally, 500 thous. IU on day 1, 1 million IU on days 2, 3, 5, previously dissolved in 20 ml of 0.9% saline, on day 4, a course of polychemotherapy is carried out according to the scheme: paclitaxel 175 mg/m2 IVFD, carboplatin (AUC 4-6) IVFD. 3 courses of immunochemotherapy are conducted with an interval of 21 days.EFFECT: method allows to neutralise the toxic reactions of chemotherapy with a significant decrease in the tumor size with appearance of its mobility, which allows to perform treatment as the full scope of surgical intervention.1 ex

Pharmaceutical composition for cancer treatment comprising interferon-alpha conjugate // 2622077
FIELD: pharmacology.SUBSTANCE: invention relates to the pharmaceutical composition comprising an interferon-alpha conjugate with the polymer and the Raf inhibitor, and can be used in medicine. The received pharmaceutical composition is used for treating cancer with k-ras mutation.EFFECT: invention provides a pharmaceutical composition having a prolonged in vivo half-life and greater anti-cancer activity than the interferon-alpha, thus reducing the introduced dose of the anticancer agent by reducing its side effects.23 cl, 6 dwg, 5 tbl, 6 ex
"viferon" application for pregnant women with hpv infection to prevent placenta infection and placental insufficiency // 2620547
FIELD: medicine.SUBSTANCE: invention can be used for prevention of placental insufficiency and placental infection for pregnant women with HPV infection. Viferon drug is applied by administering rectal suppositories in combination with intravaginal introduction of Viferon in the form of gel.EFFECT: use of the invention allows prevention of placental insufficiency and placental infection for pregnant women with PVI.4 dwg, 1 tbl
Treatment method of chronically non-healing wounds // 2620336
FIELD: medicine.SUBSTANCE: invention refers to the medicine, particularly, to the surgery, and may be used for the treatment of chronically non-healing wounds. For this purpose, on the treatment day 1, 4, 7, 10, and 13, the solution of alpha-interferon at the total dosage of 3 mln UA is injected uniformly to the bottom and along the external edges of a wound at the depth of 10 mm. Common reproduction in the outpatient conditions.EFFECT: method allows reducing a period of healing of post-operation wounds and improving the quality of life of patients by means of local immunity stimulation with the further development of active granulations.3 ex
ethod of treatment of subclinical mastitis in lactating cows // 2619862
FIELD: veterinary medicine.SUBSTANCE: method involves a joint application of the Aminoseleton tissue specimen on days 1, 3 and 5 of the treatment course, which is administered subcutaneously in the upper third of the neck at a growing dose of 40-45-50 ml. The immunomodulator is administered in a dose of 10 ml intramuscularly on days 2, 4 and 6 of treatment. Bovine recombinant interferons α and γ are used as an immunomodulator.EFFECT: method is highly effective for the treatment of subclinical mastitis in lactating cows.3 tbl, 1 ex

Liquid composition of long-acting alpha interferon conjugate // 2613905
FIELD: medicine, pharmacy.SUBSTANCE: group of inventions refers to the field of pharmacy and medicine and relates to a liquid composition (options), in which the long-acting INF conjugateα and the immunoglobulin Fc-fragment are covalently linked by a non-peptidic polymer, and includes a stabilizer with a buffer, sugar alcohol, a nonionic surfactant and an isotonic agent; at that, it does not contain human serum albumin and other potential factors harmful for the organism. The inventive method for liquid composition production and a stabilizer are also stated.EFFECT: group of inventions provides excellent storage stability of long-acting INF conjugatesα with improved durability and stability in vivo, can be safely stored for a long period of time.17 cl, 1 dwg, 6 ex, 12 tbl
ethod of treating children with acute respiratory infections accompanied with secondary immune deficiency // 2609865
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to clinical Immunology and allergology, and can be used for treating children suffering frequent episodes of acute respiratory infections accompanied secondary immune deficiency. Method involves the intranasal introduction of "Grippferon" during 5 days a week with underlying nebulization through face mask with 12.5 % solution of "Cycloferon" – 2 ml, 2 times a week and application of medical pepper of patch on skin in projection of thymus, that is performed 2 times a week for time, when in last 3 months episodes of acute respiratory infections are not registered or only one episode is registered.EFFECT: use of invention increases efficiency of antirecurrent therapy of frequent recurrent ARI episodes.1 cl, 1 ex
ethod for prevention of spontaneously occurring acute peritonitis in experimental animals // 2608133
FIELD: medicine.SUBSTANCE: invention relates to experimental medicine, veterinary science, surgery, microbiology, pharmacology. Method for prevention of spontaneously occurring acute peritonitis in rats is disclosed: daily for 8 days antibacterial peptide complex (ABPC) is introduced in dose of 4,000 IU intraperitoneally and 4,000 IU intramuscularly once a day.EFFECT: technical result is prevention of acute peritonitis in experimental animals, arising as a result of defects and caused by conventionally pathogenic bacteria.1 cl, 3 ex

ethod of producing nanocapsules of cephalosporin preparations in interferon // 2605848
FIELD: medicine.SUBSTANCE: invention relates to medicine and consists in method of producing microcapsules of cephalosporin preparations, in which envelope is interferon, core is preparations of cephalosporins. During method implementation cephalosporin preparations and E472c as surfactant are added to aqueous solution of interferon, obtained mixture is mixed in magnetic stirrer until dissolving of mixture components to produce transparent solution, then slowly chloroform is added by drops, obtained suspension is filtered, washed with chloroform and dried, wherein ratio shell:core is 3:1.EFFECT: technical result consists in simplifying and accelerating of production of nanocapsules, as well as increase of mass output.1 cl, 1 dwg, 9 ex

ethod of treating generalized cytomegalovirus infection in children of early age // 2602953
FIELD: medicine.SUBSTANCE: invention relates to medicine and can be used for the treatment of generalized cytomegalovirus infection in children of early age. To do this, when viral load in blood is 105 cop/ml or more, child is subjected to intravenous introduction of ganciclovir for 14-21 days at a dose of 5-7.5 mg/kg to reduce the viral load in the blood to 104-103 cop/ml, then ganciclovir is withdrawn and viferon 150,000 ME in suppositories is used as follows: 1 suppository 2 times a day for 10-14 days, then 1 suppository 3 times a week: Monday, Wednesday, Friday for 3-6 months till complete elimination of virus in child's blood.EFFECT: invention provides complete elimination of the virus from the blood of the young child.1 cl, 4 tbl, 3 ex

ethod of treating patients with facial pain with postherpetic ganglionitis of a head // 2601408
FIELD: medicine.SUBSTANCE: invention refers to medicine and is aimed at treating patients with facial pain with postherpetic ganglionitis of a head. Content of specific G antibodies to the herpes simplex virus (HSV) type 1 and cytomegalovirus, content of alpha and gamma interferons, serum and spontaneous interferon in blood, in the oral fluid: concentration of A secretory immunoglobulin, alpha interferon and lactoferrin level. Index of microorganisms adsorption reaction is calculated (MAR). If the values of serum and spontaneous interferon do not exceed 2 units/ml, content of specific G antibodies to HSV type 1 is from 1:2973.75 and higher, to cytomegalovirus - from 1:2916.91 and higher, of alpha interferon - from 194.78 unit/ml and lower, of gamma interferon - from 16.87 unit/ml and lower, and in the oral fluid: concentration of secretory immunoglobulin - from 225.11 mg/ml and lower, concentration of alpha interferon - from 8.6 pg/ml and lower, lactoferrin level - from 9613.3 ng/ml and lower, MAR index - from 6.5 and higher, the acyclic nucleosides group drug is prescribed in complex, anti-inflammatory agents, anti-histamine drugs, immunomodulators.EFFECT: using the invention provides increase in treatment efficacy due to comprehensive application of drug therapy preparations.1 cl, 1 ex

Inhibitor of liquid in cavities of body accumulation // 2597795
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and concerns drug for inhibiting accumulation of liquid into mammals body cavity, having accumulation of liquid in cavity of body, caused by cancer, as active substance containing covalent conjugate of interferon-beta with polyethylene glycol.EFFECT: invention provides effective treatment and removal of liquid from body cavity by systemic administration as well as by local administration.9 cl, 6 dwg, 6 ex

ethod of treating multiple sclerosis in children // 2596792
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to neurology, and can be used in medical practice for treating multiple sclerosis (MS) in children. Method involves plasmapheresis, immunocorrecting and antiviral therapy. Herewith 2 times a year with the gap of 6 months 1 session is performed of cascade plasma exchange of one volume of circulating plasma, then intravenously immunoglobulin G is introduced by drop infusion in the dose of 0.2-0.4 g/kg for 2 days. Then intravenously Ronkoleukin is introduced by drop infusion in the dose of 0.5 mg/day for two days followed by prescribing Viferon in the dose of 3 million IU a day 3 times a week for 1 month in relapsing remitting multiple sclerosis and for 3 months in secondary (or primary) progressive multiple sclerosis.EFFECT: invention usage allows to reduce the frequency of MS exacerbations, reduce indices of disability, reduce the term of treatment.1 cl, 4 tbl, 3 ex

Therapeutic agent for treating allergic and viral ocular diseases in form of gel or gel-like drops // 2595244
FIELD: medicine.SUBSTANCE: invention is intended for treating allergic and viral ocular diseases. Therapeutic agent for treating allergic and viral ocular diseases in form of gel or gel-like drops contains an antihistamine, selected from a group comprising azelastine, levocabastine, loratadine, recombinant interferon, selected from alpha, beta-, gamma-recombinant interferon, boric acid, hyaluronic acid and water. Ingredients are used in the declared ratio.EFFECT: using invention provides higher therapeutic effectiveness of treating allergic and viral ocular diseases due to prolonged action with increased time of contact between drug and eye cornea.1 cl, 6 ex

Combined therapy including vemurafenib and interferon, for use in treating cancer // 2592983
FIELD: medicine. SUBSTANCE: group of inventions relates to a combined therapy of solid tumour or cancer. Disclosed are: pharmaceutical product in form of combined preparation for specified application, containing as an active agent {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}propane-1-sulphonic acid or its pharmaceutically acceptable salt and peg-interferon alpha-2a; set of same application, including said active agents; use of {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}propane-1-sulphonic acid or its salts and peg-interferon alpha-2a in treating solid tumour or cancer; use of {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}propane-1-sulphonic acid or its salts and peg-interferon alpha-2a for preparing a drug for treating solid tumour or cancer. EFFECT: longer life of patients. 18 cl, 6 dwg, 10 tbl
Agent possessing immunomodulatory and antiviral activity // 2592201
FIELD: pharmaceutics. SUBSTANCE: invention relates to an agent possessing immunomodulatory and antiviral action. Agent having immunomodulatory and antiviral action in form of an ointment, which contains medical vaseline, anhydrous lanolin, peach oil, alpha-tocopherol acetate, human recombinant interferon alpha-2b, ascorbic acid, human serum albumin solution 10 %, calcium pantothenate, purified water, taken in a certain amount. EFFECT: said agent possesses pronounced immunomodulatory and antiviral action, is stable during storage. 1 cl, 5 ex

ethod of inhibiting infectious activity of ebola virus in experiment // 2585695
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to experimental virology, and can be used to inhibit infectious activity of Ebola virus in experiment. Method involves introduction to Guinea pigs preparation of recombinant human interferon alpha-2 before or during penetration agent in animal's body in daily dose sufficient for developing antiviral agent inhibiting activity. For this purpose, preparation “Reaferon-Lipint” in liposomal form is used in daily dose from 200,000 to 300,000 IU/kg. When simulating prevention and treatment of viral infection this preparation is introduced for 12 and 1 hours to virus infection inoculation of Ebola virus, at moment of infection and through 12, 24, 36, 48, 60, 72 hours after infection of Ebola virus.EFFECT: method provides achievement of inhibitory effect at reduction of preventive and therapeutic dose of recombinant human interferon alpha-2.2 cl, 3 tbl, 2 dwg
ethod for treatment of human systemic lupus erythematosus // 2580301
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to therapy and Immunology, and concerns treating Systemic Lupus Erythematosus. That is ensured by integrated treatment, consisting of two ten-days stages. First stage involves intramuscular introduction of preparations of interferon, anti aggregants and/or detoxification therapy combined autohemotherapy in form of mixture in one syringe of auto blood in amount of 2 ml and human immunoglobulin normal in amount of 1.5 ml for following 5 days. Second stage involves oral introduction of interferon inductors and intravenous infusion therapy with hepatoprotectors. Such courses of treatment is carried out once in three months. Therapeutic courses are repeated to normalize immunological, laboratory values and improving clinical presentation of patient.EFFECT: method provides the stable remission at decrease of dependence of cytostatic agents and glucocorticosteroids.3 cl, 2 ex
ethod for prevention of local recurrence in transanal endoscopic resection of rectum cancer // 2578816
FIELD: medicine.SUBSTANCE: invention can be used for prevention of local recurrence after transanal endoscopic resection of rectum cancer in patients with initial forms of rectal cancer T1N0M0. For this purpose during the surgical intervention, after a full thickness resection of the intestinal wall with a part of mezorectal cellular tissue and removal of the preparation the mezorectal cellular tissue is infiltrated with 20 ml of ozonised physiologic saline in the ratio of 1000 mcg/l. Then a preparation of interferon alpha 1 is introduced into the mezorectal cellular tissue in the amount of 1 million IU. After that the mezorectal cellular tissue is sprayed with 1 g of capecitabine powder. Then, at the following stage, the rectal wall is closed in a standard way.EFFECT: method provides for reduction of a rate of local disease recurrence.1 cl, 2 ex
ethod for prevention of infectious-inflammatory complications of transanal endoscopic resection of rectum for tumours // 2578811
FIELD: medicine.SUBSTANCE: invention can be used for prevention of infectious-inflammatory complications during transanal endoscopic resection of rectum apropos benign and malignant tumours. For this purpose during transanal endoscopic resection of rectum under the condition of intestinal content ingress into the mezorectal cellular tissue, presence of inflammatory changes of the rectal wall in the area of the tumour, the mezorectal cellular tissue is infiltrated with 20 ml of ozonised physiologic saline in the amount of 1000 mcg/l. Then a preparation of interferon alpha 1 is introduced into the mezorectal cellular tissue in the amount of 1 million IU. After that, mezorectal cellular tissue is sprayed with 1 gram of metronidazole powder. Then, at the following stage, the rectal wall is closed in a standard way.EFFECT: simple to implement method enables to individualise the therapeutic approach when predicting a high risk of development of infectious-inflammatory complications, ensuring a reduced rate of complications development and of the rate of rectum rhaphes lack.1 cl, 2 ex

ethod for comprehensive endoecological rehabilitation of human body // 2576791
FIELD: medicine.SUBSTANCE: invention relates to medicine, particularly cosmetology and may be used for complex cleansing human body, endoecological rehabilitation. System of actions is 10-day course, at beginning of which is a single administration of Dekaris 150 mg in morning after breakfast. Daily within one therapeutic session, next series of procedures: stimulating interstitial humoral transport and lymphatic drainage tissues by pressure therapy apparatus BTL Lymphastim. Phonophoresis frequency from 800 to 3,000 kHz, intensity of not more than 1 W per cm2 on biologically active points of liver to meridian homoeopathic preparations having function stimulation of biliary excretion and antitoxic liver function. Cleansing with choleretic charges, immediately after whole bowel irrigation with administration of enterosorbent. After 2 hours is bifidumbacterin rectal suppositories in 1 suppository daily orally 10 doses of bifidumbacterin probiotic forte, as well as preparation group interferons through rectum, such as kipferon, followed by oral administration of vitamin-mineral complex, which is selected individually in accordance with available readings of patient. Also, three times a week after phonophoresis procedure, before tubage, mesotherapy of tender zones is performed - in liver projection using organ-specific homoeopathic preparations. Additionally, after pressure therapy procedures may be conducted to patient in SPA-capsule “DERMALIFE”.EFFECT: method is based on most physiological performance of known procedures in most physiological for body sequence and provides most complete recovery of internal environment of body - endoecological rehabilitation, with long - up to 3 months - storage of received positive effects on biliary, anti-toxic liver function, normalisation of internal microflora, immunity, blood biochemical parameters.3 cl, 2 dwg, 1 tbl

Peg-modified human interferon β-1a molecule with antiviral, immunomodulatory and antiproliferative activity, with improved stability, reduced immunogenicity, improved pharmacokinetic and pharmacodynamic parameters, suitable for medical use, and immunobiological formulation based thereon // 2576372
FIELD: biotechnologies.SUBSTANCE: invention relates to biotechnologies, especially to obtaining PEG conjugate and human interferon-β1a, and may be used in medicine. Attachment of a PEG linear molecule 20-40 kD to human interferon-β-1a produced a conjugate of formula (I): , wherein: n - an integer from 454 to 909; m - an integer ≥ 4; IFN is a natural or recombinant human interferon-β-1a. Compared to natural human interferonβ-1a, the conjugate of formula (I) provides a higher stability, reduced immunogenicity and improved pharmacokinetic and pharmacodynamic parameters.EFFECT: conjugate may be used for treatment of various autoimmune, viral, and oncological diseases.28 cl, 10 dwg, 9 tbl, 20 ex

Pegylated recombinant consensus interferon version conjugate and preparation method and use thereof // 2575796
FIELD: chemistry.SUBSTANCE: invention relates to biotechnology, specifically to obtaining a pegylated recombinant consensus interferon version conjugate, and can be used in medicine. The invention enables to obtain an interferon-based anti-HBV drug, in which the activated PEG molecule is linked through a short linker to the α-amino group of glycine at the N-end of the recombinant consensus interferon version.EFFECT: invention enables to obtain an anti-HBV drug with high water solubility and low toxicity and immunogenicity compared to a natural interferon.3 cl, 6 dwg, 12 ex

ethod for obtaining alpha5-interferon protein // 2575598
FIELD: chemistry.SUBSTANCE: invention relates to field of biotechnology and can be used for recombinant production of α5-interferon. E. coli cell - IFNa5 producent is cultivated with application of carbon solution to feeding with glucose as carbon source, containing the following components per litre, mg: 90-111 of iron (III) chloride hexahydrate, 12.15-14.985 of calcium chloride dehydrate, 20.25-24.975 of zinc (II) sulphate heptahydrate, 4.5-5.55 of manganese (II) sulphate monohydrate, 9-11.1 of copper (II) sulphate pentahydrate, 3.42-4.218 of cobalt chloride hexahydrate, 0.9-1.11 of sodium molybdate dehydrate and 2.07-2.553 of boric acid. Fermentation medium is, in fact, free of animal- or yeast-derived components and is characterised by content of the following components per litre, mg: 28.5-36.9 of iron (III) chloride hexahydrate, 3.8475-4.9815 of calcium chloride dehydrate, 6.4125-8.3025 zinc (II) sulphate heptahydrate, 1.425-1.845 of manganese (II) sulphate monohydrate 2.85-3.69 of copper (II) sulphate pentahydrate, 1.083-1.4022 of cobalt (II) chloride hexahydrate, 0.285-0.369 of sodium molybdate dehydrate and 0.6555-0.8487 of boric acid.EFFECT: invention makes it possible to minimise incorporation of additional methionine residue into N-terminal part of polypeptide chain and generation of its oxidised molecules.10 cl, 13 dwg, 3 tbl, 4 ex

New formulation containing polyethylene glycol (peg) conjugated interferon alpha-2beta characterised by less painful administration // 2572800
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine and concerns a composition for subcutaneous administration, containing PEGylated interferon alpha and additives, particularly edetate disodium dehydrate, sodium acetate trihydrate, glacial acetic acid, an osmotic agent. The group of inventions also concerns a method for producing the above composition; a kit comprising a syringe or flask filled with the above composition, and an instruction for use.EFFECT: group of inventions provides less painful administration of the composition.15 cl, 7 ex, 5 dwg, 13 tbl

Composition of aqueous solution of recombinant human interferon alpha-2 for rectal administration // 2564951
FIELD: medicine.SUBSTANCE: composition of an aqueous solution of recombinant human interferon alpha-2 contains: recombinant human interferon alpha-2 25.0-200.0 thousand International Units, sodium alginate 10.0-100.0 mg, antioxidant oxidised glutathione 0.006-0.1 mg, the antimicrobial preserving agent Nipagin 0.2-1.8 mg, the stabilising agent Polysorbate 80 (Tween 80) 0.01-1.0 mg, sodium chloride 5.8-7.5 mg, a buffer compound for balancing pH 4.5-7.0 10.0-25.0 mM, water - the rest up to 1 ml.EFFECT: using the given composition enables creating the aqueous solution of extended release recombinant human interferon alpha-2 for rectal administration.3 cl, 4 tbl, 2 dwg

Paediatric compositions for treating multiple sclerosis // 2562571
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to medicine and pharmacology, and concerns treating multiple sclerosis. There are presented: a pharmaceutical composition for mentioned application in children containing 0.25 mg and less of 2-amino-2-[2-(4-C2-C20alkylphenyl)ethyl]propane-1,3-diole or its pharmaceutically acceptable salt administered once a day; using the above compound (FTY720) in a dose of 0.25 mg or less for preparing a therapeutic agent for treating, preventing or delaying multiple sclerosis in the paediatric patients once a day, and a related method of treating, preventing or delaying multiple sclerosis in the paediatric patients.EFFECT: treatment is effective and tolerated well by the adolescents.15 cl, 7 ex

Novel avian cytokines and genetic sequences coding thereof // 2562108
FIELD: medicine.SUBSTANCE: invention relates to the field of genetic engineering. Claimed is an isolated molecule of nucleic acid for the therapy of hens or for the support, stimulation or enhancement of their immune response, selected from a number of molecules, which code lambda-interferon (INF-λ)) of hens, represented in SEQ ID NO: 1 or 3, or molecules, which represent a nucleic sequence, which codes an amino acid sequence, given in SEQ ID NO: 2 or 4, or a sequence of nucleic acid, capable of hybridising with SEQ ID No: 1 or 3 in high-stringency conditions, an isolated polypeptide, a therapeutic method and application for the therapy of hens are also claimed.EFFECT: invention makes it possible to realise therapy and diagnostics of hens.13 cl, 4 tbl, 15 dwg, 2 ex

Ophthalmic composition of eye drops for treating antibiotic-resistant infectious-inflammatory eye diseases // 2561049
FIELD: medicine.SUBSTANCE: ophthalmic composition of eye drops for treating antibiotic-resistant infectious-inflammatory eye disease consists of an antiseptic specified in a group of: polyhexanide biguanide, chlorhexidine, boric acid, recombinant interferon specified in a group of: recombinant interferon-alpha, recombinant interferon-beta, recombinant interferon-gamma, and dexpanthenol, wherein as a consistence-forming base, it contains an ingredient specified in a group of: macrogol 400, macrogol 4000, polyvinyl pirrolidone, polyethylene glycol, dextrane and hypromellose. The ingredients in the composition are taken in certain ratio, wt %.EFFECT: treating the antibiotic-resistant infectious eye diseases with no antibacterial agents additionally used.4 ex

Gel-like eye drops for treatment of inflammatory allergic, bacterial, viral, traumatic and dystrophic eye diseases // 2561046
FIELD: pharmacology.SUBSTANCE: eye drops contain recombinant interferon, selected from the group: alpha-, beta-, gamma-recombinant interferon, antioxidant, preservative, antihistamine medication, gel-forming preparation and water.EFFECT: creation of gel-like eye drops, which simultaneously provide anti-inflammatory and immunomodulating action, which do not contain toxic preservatives and render moistening and lubricating effect without manifestation of side effects and irritating action on eye cornea and well-tolerated by patients.5 ex

Tabletted pharmaceutical composition for treating severe forms of viral infections // 2559179
FIELD: medicine.SUBSTANCE: invention represents a tabletted pharmaceutical composition for treating severe forms of viral infections characterised by the fact that as therapeutic agents it contains interferon specified in a group of: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, antioxidants specified in a group of: mexidol, emoxypine, dibunol, alpha-lipoic acid, carnitine chloride; amino acid specified in a group of: acetyl cysteine, cysteine, lysine, arginine; anabolic regenerants specified in a group of: potassium orotate, riboxine, methyluracyl, as well as a form-building base with the ingredients in the composition taken in certain relation, g per 1 g of the mixture.EFFECT: extending the range of products for treating severe forms of viral infections, high bioavailability and reducing length of treatment.5 cl, 1 tbl, 4 ex

ethod of treating epstein-barr viral infection in hiv-infected children // 2555474
FIELD: medicine.SUBSTANCE: treating an active form of Epstein-Barr viral infection in the children with an inactive HIV infection involves conducting high-active antiretroviral therapy accompanying administering inosin pranobex prescribed orally from the first day of treatment in a daily dose of 50 mg/kg of body weight, 3-4 times a day to make three courses of 10 days each, as well as using suppositories of interferon alpha-2b + taurine per rectum according to the schedule: for the first 10 days of treatment - one suppository two times a day - in the morning and in the evening, every 12 hours; further - one suppository at the bedtime every second day for three months. The method enables reducing a rate and an intensity of the Epstein-Barr viral infection symptoms by reducing the lymphocyte, blood plasma, oropharyngeal mucus Epstein-Barr virus content and improving the immunological status presented by normalising CD3+ lymphocyte, CD4+ lymphocyte, CD95+ lymphocyte, annexin-V+ lymphocyte, annexin-V+/propidium+ lymphocyte, CD19+ lymphocyte counts.EFFECT: reducing the rate and intensity of symptoms.2 tbl, 2 ex

Anti-enteroviral and immunostimulating agent // 2554761
FIELD: medicine.SUBSTANCE: invention represents an oral anti-enteroviral and immunostimulant agent in the form of capsules containing interferon and additives, differing by the fact that a therapeutic substance is human recombinant interferon alpha-2b immobilised on polyethylene glycol, having a molecular weight of 1.5 kD by a physical method of binding by an accelerated electron flow in a dose of 1.5 Mrad. The ingredients in the agent are taken in a certain ratio.EFFECT: extending the range of anti-enteroviral agents possessing immunostimulant properties.6 ex, 10 tbl

Cytokine-containing medication, possessing antiviral, antimicrobial, immunomodulating and anti-inflammatory action for prevention and treatment of infection diseases // 2554495
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmacology, in particular, to medication, possessing antiviral, antimicrobial, immunomodulating and anti-inflammatory action, in form of drops, spray, gel and solution for injection for treatment and prevention of infection diseases: herpes, acute respiratory viral infections, hepatitis, HIV-infections, viral disease. Medication according to invention contains complex of cytokines with Trilonum B, immobilised on biologically compatible polymer as carrier.EFFECT: obtaining medication, possessing antiviral, antimicrobial, immunomodulating and anti-inflammatory action.3 cl, 6 ex

Encapsulated lyposomal antiviral agent based on human interferon alpha-2b for vaginal application // 2552851
FIELD: medicine.SUBSTANCE: invention represents an encapsulated liposomal antiviral agent based on human interferon alpha-2b for vaginal application, characterised by the fact that each capsule is made in the form of a hollow coating, which encloses a powder excipient and liposomes distributed in the excipient, and sodium alginate, a water-soluble polymer gel former; the excipient consists of lactose, sodium chloride, 12-aqueous disodium hydrogen phosphate and sodium dihydrogen phosphate, whereas each of the liposomes represents a hollow coating containing lecithin, cholesterol and alpha-tocopherol, and a nucleus inside the coating and containing recombinant human interferon alpha-2; the ingredients of the agents are taken in a certain ratio, mg.EFFECT: maintaining the storage activity of recombinant human interferon alpha-2 and prolonged action in vaginal application.2 cl, 3 dwg, 6 tbl, 6 ex
Pharmaceutical composition for producing antiherpetic mixed vaccine and based dosage form // 2552341
FIELD: medicine.SUBSTANCE: pharmaceutical composition contains a viral preparation containing types 1 and 2 herpes simplex viruses inactivated by formalin or gamma radiation, and an immunocompetent substance. The immunocompetent substance is presented by interferon and a combination of at least two independent amino acids in the following proportions: inactivated types 1 and 2 herpes simplex viruses - 5 mln of plaque-forming units per 1 ml of the suspension, interferon - 150-250 thousand International units/ml, amino acids - 0.27 mg/ml.EFFECT: adding interferon to the composition as an adjuvant, and also a combination of two irreplaceable amino acids enables creating the high-effective herpes vaccine, preparing a based dosage form in the form of suppositories that makes the vaccine applicable in paediatric practice.4 cl, 3 ex
ethod for preventing influenza by combined application of interferon gamma and inactivated anti-influenza vaccine // 2546540
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to immunology, and can be used for preventing influenza. That is ensured by combined single administration of cytokine that is ensured by interferon gamma, and an inactivated anti-influenza vaccine. Interferon gamma is administered intermuscularly or subcutaneously in a dose of 0.5 ml 100,000 International Units±10% into the upper one-third of one shoulder; then the inactivated anti-influenza vaccine 0.5ml based on vaccine influenza viral strains (H5N1) Orniflue containing heamagglutinin in a minimum dose of 15 mcg/dose for this vaccine is administered intramuscularly into the upper one-third of the other shoulder.EFFECT: method enables increasing immunogenicity and protective activity of the vaccine ensured by single vaccination and reducing side effects on the antigen by the immune response modulation.9 tbl, 1 ex
ethod of treating chronic pain syndrome // 2545915
FIELD: medicine.SUBSTANCE: suppositories, containing uniformly distributed in one suppository recombinant human interferon-alpha-2b in an amount of 400000-600000 IU and immunoglobulins IgA, IgM and IgG in an amount of 0.1-0.3 g, are additionally rectally introduced as the second medication to an adult patient in case of the long-term introduction of an opioid-containing medication. The dose constitutes 2-3 suppositories 2-3 times per day with the reduction of the daily dose by 1-3 suppositories in case of the reduction of pain sensation to 2-3 points by a ten-point scale and expressed sedation. If pain sensation increases to 6-8 points by the ten-point visual analogue scale, the daily dose is increased by 1-3 suppositories.EFFECT: application of the claimed method makes it possible to ensure the prevention of the opioid dose increase and an increase of the level of antibodies to interferon-alpha in the patients' blood serum in case of the long-term application of opioids.5 ex

Therapeutic agent in form of gel for treating herpetic infection manifestations in patients with burns and cold injuries // 2544163
FIELD: medicine.SUBSTANCE: therapeutic agent contains recombinant interferon specified in a group of: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, metronidazole, fluconazole and/or voriconazole, and a pharmaceutically acceptable base in the following proportions, g per 1 ml of the mixture: recombinant interferon, international units 100-10,000,000; metronidazole 0.00001-0.5; fluconazole and/or voriconazole 0.00001-0.5; pharmaceutically acceptable base - the rest. Besides, the therapeutic agent contains boric acid in an amount of 0.00001-0.5 g and hypromellose in an amount of 0.00001-0.5 g. As a pharmaceutically acceptable base, it contains macrogol 400 or macrogol 1500, or macrogol 4000.EFFECT: higher efficacy of the compound.2 cl, 5 ex
ethod of treating atopic dermatitis in children with secondary immunodeficiency syndrome // 2542421
FIELD: medicine.SUBSTANCE: common therapy is conducted in the patient according to standard regimen. Additionally, from the first therapeutic day, Ananferon for kids and Virefon, suppositories are prescribed. Anaferon for kids is administered subglosally without regard to food in a dose of 1 tablet once a day for 2 months. Viferon, rectal suppositories are used 2 times a day every 12 hours for 30 days according to the schedule: for the first 10 days, 1 suppository of 1,000,000 international units, for the following 10 days, 1 suppository of 500,000 international units and then 1 suppository of 150,000 international units.EFFECT: using the given method enables normalising the immune status values, prolonging the remission of clinical manifestations of atopic dermatitis in the children with secondary immunodeficiency syndrome.2 ex
Pharmaceutical composition for treating trophic ulcers and persistent wounds of various origins in form of ointment // 2539383
FIELD: medicine.SUBSTANCE: pharmacological composition contains a therapeutic agent and a pharmaceutically acceptable base. As a therapeutic agent, it contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, as well as hypromellose, boric acid as an antiseptic, anesthesin or lidocaine as local anaesthetics in the following proportions, g per 1 ml of the mixture: recombinant interferon, IU 100-10,000,000, hypromellose 0.00001-0.5, boric acid 0.00001-0.5, anesthesin or lidocaine 0.00001-0.5, a pharmaceutically acceptable base - the rest. Besides, the pharmaceutical composition contains heparin in an amount of 0.00001-0.5 g; antibiotics specified in a group of: baneocin, levomycin, tetracycline, amoxicilline in an amount of 0.00001-0.5 g. And as a pharmaceutically acceptable base, the pharmaceutical composition contains macrogol 400, or macrogol 1500, or macrogol 4000.EFFECT: more effective treatment.4 cl, 9 ex
Pharmaceutical composition for treating individuals suffering xerostomia // 2538699
FIELD: medicine.SUBSTANCE: pharmaceutical composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, metronidazole, hypromellose, antiseptics and a consistency base in the following relation of ingredients, g per 1 ml of the mixture: recombinant interferon, IU 100-10,000,000; metronidazole 0.00001-0.5; hypromellose 0.00001-0.5; antiseptics 0.00001-0.5; consistency base - the rest. Besides, the pharmaceutical composition contains antibiotics specified in a group: baneocin, levomycin, tetracycline, amoxicilline in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains antiseptics specified in a group: boric acid, salicylic acid, hydrogen peroxide, chlorhexidine, ethanol, povidone iodine, silver nitrate, silver sulphadiazine in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains anesthesin or lidocaine as local anaesthetics in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains vitamin A or beta-carotene as food colorants in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains flavouring agents specified in a group of: tea tree oil, menthol oil, eucalyptus leaf oil in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains macrogol 400, or macrogol 1500, or macrogol 4000 as a consistency base.EFFECT: more effective treatment.7 cl, 11 ex
Pharmaceutical composition for treating gastroduodenal ulcer, possessing immunomodulatory, antiviral, antibacterial, anti-inflammatory, antioxidant and regenerative effect in form of tablets, capsules or gel // 2538697
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E.EFFECT: invention has the integrated body effect promoting faster healing of the mucosal defect accompanying the aggravated gastroduodenal ulcer and preventing recurrences, including by the eradication effect.6 cl, 5 ex
Pharmaceutical composition for preventing and treating infectious-inflammatory diseases of various origins by oromucosal administration // 2538433
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition in the form of tablets for oromucosal administration in treating infectious-inflammatory oropharyngeal diseases. The composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; amino acid specified in a group: arginine, histidine, glycine, glutathione, lysine, methionine, cysteine; an antiseptic, a preserving agent, flavours specified in a group: tea tree oil, eucalyptus leaf oil, mint leaf oil and a consistence base.EFFECT: invention makes the composition applicable in fragile and frequently ill patients for reducing a disease recurrence.7 cl, 1 ex
ethod of treating affection of vegetative parasympathetic nodes of head of herpes-virus etiology // 2538083
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to dentistry and maxillofacial surgery, and can be applied for treating affection of vegetative parasympathetic nodes of head of herpes-virus etiology. For this purpose introduced are: famciclovirum in dose 500 mg 3 times per day for 10 days, ketorop in dose 1 tablet 2 times per day after meal for 7 days, tavegyl in dose 1 tablet 1 time per day before going to bed for 10 days, neuromultivit in dose 1 tablet 2 times per day for 30 days, in addition, additionally introduced is viferon in form of rectal suppositories in dose 1 suppository (500000) 1 time per day for 10 days. Patient takes all medications mentioned above simultaneously. When the course of viferon intake is over, cycloferon in tablets is administered in tablets with dose 150 mg with the schedule of intake as follows: 1-st day - 1 tablet 2 times per day; 2-nd day - 1 tablet 1 time per day; 4, 6, 8, 11, 14, 17, 20, 23-rd day - 1 tablet 1 time per day, after intake of which administered is immunorm in dose 1 tablet 3 times per day for 30 days.EFFECT: method makes it possible to increase therapeutic effect due to simultaneous impact on herpes virus and separate links of immunity with increase of remission and reduction of term of its development, absence of aggravations and long support of organism and virus equilibrium.2 tbl, 2 ex
Pharmaceutical composition for prevention and treatment of papillomatosis of various localisation // 2537232
FIELD: medicine.SUBSTANCE: invention represents a pharmaceutical composition for treating papillomatosis of various localisations, containing a recombinant interferon specified in a group: recombinant interferon-alpha, recombinant interferon-beta, recombinant interferon-gamma, and further cysteine, and vitamin A or beta-carotene, and a pharmaceutically acceptable carrier, wherein the ingredients in the compositions are taken in certain proportions, g per 1 g.EFFECT: increasing therapeutic efficacy of the treatment, reducing the length of treatment and minimising the potential recurrence.10 cl, 13 ex
ethod of treating patients after hemorrhoidectomy with immune stimulation of surgical wound healing // 2537127
FIELD: medicine.SUBSTANCE: haemorrhoidectomy involving removing haemorrhoids en bloc with an anal wound closure is followed by daily dressings from the first postoperative day with using the antibacterial preparation Levomecol. That is combined with a therapeutic parenteral administration of standard analgesics and taking sitting baths and conducting a local physiotherapy. The preoperative preparation involves prescribing the complex immunomodulator Kipferon presented in the form of suppositories containing 500000 IU of interferon alpha-2 and 60 mg of complex immunoglobulin preparation. The preparation is administered in a dose of one suppository twice a day for 5 days preceding the haemorrhoidectomy. Then, administering the preparation is continued once a day in the same dose from the second to the eleventh postoperative day. The preoperative preparation is also added with prescribing the phlebotonic diosmin (Venarus, Detralex) orally in a dose of 500 mg twice a day for 3 days preceding the haemorrhoidectomy and continued in the same dose twice a day from the first to eighth postoperative day. Besides, from the second postoperative day the osmotic laxative Lactulose is administered orally in a dose of 15-25 ml once until the patient has an unassisted defecation.EFFECT: lower postoperative post-defecation pain syndrome as estimated by VAS analogue scale, less manifested perianal tissue oedema within the operative tissues, shorter wound epithelisation as shown by a cytological pattern of impression smears, achieved adequate elimination of the postoperative complications in the form of bleedings, reflex urinary retention, formation of deforming adhesions, reduced bacterial content of the anal wounds, shorter time of patient's anal sphincter hypertonus, as well as adequate time of postoperative defecation recovery.3 ex
Antifungal therapeutic preparation in suppositories for children // 2535068
FIELD: medicine.SUBSTANCE: invention represents an antifungal preparation in suppositories for children containing recombinant human interferon 2α and fluconazole, wherein lysozyme, Licopid and dimephosphone are additionally introduced.EFFECT: preparation possesses the high clinical effectiveness in the fungal diseases in children that leads to reducing the length of treatment and prolonging the intercurrent period.1 tbl, 3 ex

ethod of correction of immune deficiency and prevention of gastrointestinal diseases of new-born calves // 2535014
FIELD: veterinary medicine.SUBSTANCE: method comprises giving to calves to drink the tincture of the combination herbal medicinal product - the grass of St. John's wort, meadowsweet, common yarrow, common nettle, rhizome of leather bergenia, root and rhizome of marsh cinquefoil, Scotch pine needles. At that the tincture fermented with microorganisms "EM Kurung" is used. The tincture is prepared by mixing 200 ml the tincture of the combination herbal medicinal product with 40 ml of the finished product "EM Kurung" and maintaining at the temperature of 18-20°C during the day, followed by filtration. EM-preparation "Baikal EM 1" is given to dry cows for 30 days prior to calving as a single dose in a dose of 30 ml/head. Mixoferon, sedimin and nitamin are additionally prescribed to new-born calves according to the following schedule: from the second feeding the tincture of the combination herbal medicinal product is watered with colostrum, fermented with microorganisms of EM-preparation "EM Kurung" at a dose of 150 ml/head dualfold for 10 days. On the 1, 2 and 8 day of life, mixoferon is injected intramuscularly at a dose of 9 ml/head. On the 1 and 8 day of life - nitamin and sedimin at a dose of 4 ml/head.EFFECT: use of the claimed method enables to increase the immunobiological reactivity, energy of growth, provides prevention of gastrointestinal diseases of new-born calves.4 tbl, 3 ex
ethod of treating moderate house atopic bronchial asthma in patients with immune deficiency suffering from frequent acute respiratory infections // 2533284
FIELD: medicine.SUBSTANCE: treating moderate house atopic bronchial asthma in the patients with immune deficiency suffering from frequent acute respiratory infections is ensured by administering Grippferon intranasally 5 days a week with a leech therapy accompanied by a subcutaneous allergen-specific immune therapy with causally relevant allergens. The leech therapy is performed by applying one medical leech on the skin in a projection of the thymus twice a day for the period of time with no ARI episodes recorded over the last 3 months. The allergens are administered endolymphatically in the proximal direction from a cuff applied on a forehand, and pressure is maintained at 40 mm Hg for 60 minutes with an underlying basic therapy with the Symbicort preparation.EFFECT: using the method enables providing the higher clinical effectiveness in anti-recurrent therapy of the frequent ARI episodes in the patients suffering from the moderate form of bronchial asthma, reducing the number and length of the ARI episodes, preserving control over the asthmatic symptoms with reducing a dose and a frequency of the preparations of the bronchial asthma therapy.1 ex
 
2551101.
Up!